Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07393633 · ClinicalTrials.gov registry record
Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy
A clinical trial of Gynecologic Cancers, sponsored by University of Tennessee Graduate School of Medicine.
- Completed
- Registry status
- 43
- Enrollment target
- 1
- Study location
NCT07393633 is a study of Gynecologic Cancers that has completed, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 43 participants, below the 430-participant average among 10 other Gynecologic Cancers trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07393633, a study of Gynecologic Cancers, has completed, sponsored by University of Tennessee Graduate School of Medicine.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
It is well established that cancer cells have fundamentally altered metabolism, which contributes to tumorigenicity and malignancy. For years, research findings supported that the universal property of all cancer cells was to increase glycolytic flux for anaerobic glycolysis (i.e., Warburg effect), which was accepted as the dominant pathway for energy metabolism. Fortunately, by understanding these changes in cellular metabolism multiple new approaches to cancer therapy, focused on reprogramming the energy metabolism of the cell. Recently, further investigation in the field found that cancer cells exhibit multiple alterations in metabolic pathways, not only glycolysis. Alterations in lipid metabolism in cancer cells have recently been recognized as potential targets for therapeutic interventions due to its role in cellular proliferation, energy storage, and the generation of signaling molecules. Numerous cancer types can rely on lipids as an energy source, increasing fatty acid synthesis and degradation to promote proliferation and metastasis. Several therapeutic agents utilized in gynecologic malignancies impact lipid metabolism. The objective of the proposed study will be to determine the impact of cancer directed therapy on the lipid metabolism of non-malignant tissues. No study to date has assessed whole-body lipid metabolism in patients undergoing chemotherapy (i.e. cytotoxic chemotherapy and/or immunotherapy). These novel findings will provide crucial knowledge about the dysregulation of whole-body metabolism in patients receiving chemotherapy for treatment of gynecologic cancer.
Conditions Studied
Study Locations (1)
Tennessee
- University of Tennessee Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2026-01-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07393633
The ClinicalTrials.gov registry entry for NCT07393633 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 430-participant average among 10 other Gynecologic Cancers trials with a reported enrollment target (90% lower). The listed sponsor is University of Tennessee Graduate School of Medicine, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gynecologic Cancers appearing as the primary indexed condition, and to 0 interventions.
NCT07393633 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT07393633 about?
NCT07393633 is a clinical study titled "Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy". It is well established that cancer cells have fundamentally altered metabolism, which contributes to tumorigenicity and malignancy. For years, research findings supported that the universal property of all cancer cells was to increase glycolytic flux for anaerobic glycolysis (i.e., Warburg effect), ...
What is the current status of trial NCT07393633?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2024-08-01. Estimated completion is 2026-01-24.
What conditions does trial NCT07393633 study?
This clinical trial studies the following conditions: Gynecologic Cancers.
Who is sponsoring clinical trial NCT07393633?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07393633 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Proactive Costs of Care Study
RECRUITING · NA
-
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
RECRUITING · NA
-
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
RECRUITING · Phase 1
-
Communication About Sexual Health in Gynecologic Cancer
RECRUITING · NA
-
Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
RECRUITING
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.